Lytix Biopharma AS
OSE:LYTIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Lytix Biopharma AS (LYTIX) under the Base Case is NOK per share. Compared with the current market price of 9.74 NOK, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Our estimate of what one share is worth.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Lytix Biopharma AS Does
Lytix Biopharma AS is a Norwegian biotechnology company that develops cancer medicines based on the body’s own immune system. Its core idea is to make tumor cells easier for the immune system to recognize and attack, rather than relying only on traditional chemotherapy or surgery. The company’s work centers on drug candidates designed for use in oncology, especially in tumors that are hard to treat with standard approaches.
- Headquarters
- Norway NO
- Employees
- 14
- IPO date
- Jun 14, 2021
Earnings Waterfall
Lytix Biopharma AS
What is the Intrinsic Value of one LYTIX stock?
The intrinsic value for Lytix Biopharma AS (LYTIX) under the Base Case is NOK.
Is LYTIX stock undervalued or overvalued?
Compared with the current market price of 9.74 NOK, the stock appears .